Important data using ResistancePlus® MG to investigate over 1500 symptomatic vaginitis patients. Mycoplasma genitalium (Mgen) infection was more prevalent in women with bacterial vaginosis (BV) (7.0% Mgen positive) compared with...
Mycoplasma genitalium (Mgen) infections treated using resistance guided therapy led to high cure rates and low levels of de novo resistance, according to latest data from Melbourne Sexual Health published...
The Therapeutic Goods Administration (TGA) have cleared ResistancePlus® MG FleXible for the Cepheid GeneXpert® System, and it is now available for sale in Australia. This announcement further expands access to...
ResistancePlus® MG FleXible for the Cepheid GeneXpert® System is now CE-IVD and available for sale in Europe. The test detects the sexually transmitted infection (STI) Mycoplasma genitalium (Mgen) and markers...
This is the first commercially available test in Canada combining identification and therapeutic guidance information to support Resistance Guided Therapy for management of Mycoplasma genitalium (Mgen). Current Canadian management guidelines...
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Designation for ResistancePlus® GC - expediting the path towards clearance. This is the first commercially available molecular test that can...
PlexPCR® RespiVirus received clearance from the Australian Therapeutic Goods Administration (TGA), bringing much needed workflow advantages in time for the busy 2019 flu season. The test utilises market-leading multiplex technology...
SpeeDx have successfully settled into new U.S. Headquarters at the Texas Health CoLab in Austin Texas. Chosen for its synergy in supporting progressive and innovative health solutions, the technology hub...
ResistancePlus® GC received clearance from the Australian Therapeutic Goods Administration (TGA) today. Launched in December with CE-IVD mark for sale in Europe, Australian laboratories can now access this world-first diagnostic...
SpeeDx announced submission of the PlexPCR® RespiVirus test to the Therapeutic Goods Administration (TGA), with anticipated clearance in time for the Australian 2019 flu season. The test utilises market-leading PlexPCR®...